Novartis’ Serelaxin Down But Not Out: Panel Votes Against Approval But Supports Further Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee unanimously reject Novartis’ acute heart failure treatment but express optimism in product, encouraging more, better studies.